Skip to content

Kaneka Endovascular Embolization and Protection

Kaneka Endovascular Embolization and Protection

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05563051
Acronym
KEEP
Enrollment
164
Registered
2022-10-03
Start date
2022-12-13
Completion date
2025-12-31
Last updated
2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysm Cerebral

Keywords

aneurysm, coil, i-ED COIL, embolization, neuro endovascular

Brief summary

Prospective, multi-center, non-randomized registry / study, up to 164 patients enrolled and followed at 180 days +/- 45 days and again at 365 days +/- 90 days post procedure

Detailed description

Assess and describe real world clinical data on i-ED coils Characterize the acute and long-term performance of iED coils when used for treating for an intracranial aneurysm May be used alone or in combination with other adjunctive device(s) Study Duration Anticipated timeline for study: Patient enrollment in 18 - 24 months Completion of follow-up 12 months after last patient enrolled

Interventions

DEVICEi-ED COIL

The i-ED COIL System (i-ED COIL and detachment box) are intended for the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.

Sponsors

Kaneka Medical America LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Target aneurysm of 4mm - 14mm in size * Ruptured or unruptured * Suitable for embolization with coils * May be treated with or without assist devices

Exclusion criteria

* Unstable neurological deficit in unruptured cases (condition worsening within last 90 days) * Pre-planned staged procedure of target aneurysm * mRS score 3 or more * Hunt Hess Score more than 3 for subjects with ruptured aneurysm * Evidence of active infection (e.g.,fever, temperature \>38 degrees C and/or WBC \>15,000)

Design outcomes

Primary

MeasureTime frameDescription
Adequate Occlusion12 monthsProportion of subjects who achieve Adequate Occlusion (Modified Raymond-Roy I or II Classification)

Secondary

MeasureTime frameDescription
Complete Occlusion12 monthsComplete occlusion at 1 year (Modified Raymond-Roy I)
Packing Density12 monthsAneurysm volume and percent of aneurysm packing for coil embolization. Packing density will be evaluated based on aneurysm volume and coil volume
Modified Rankin Score12 monthsModified Rankin Score (Scale from 0-6), the lower the score the better - 0 No symptoms and 6 is dead. 1. No significant disability. Able to carry out all usual activities, despite some symptoms. 2. Slight disability. Able to look after own affairs without assistance but unable to carry out all previous activities. 3. Moderate disability. Requires some help, but able to walk unassisted. 4. Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5. Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6. Dead
Retreatment12 monthsAny retreatment of the aneurysm, surgically or interventional embolization
Adverse events12 monthsDevice or procedure related adverse events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026